Alliance for Pandemic Preparedness

April 22, 2021

Immunogenicity of SARS-CoV-2 Vaccine in Dialysis



Keywords (Tags): ,

  • [Pre-print, not peer-reviewed] 89% of 186 dialysis patients developed anti-SARS-CoV-2 spike antibodies following two doses of mRNA vaccines (Pfizer-BioNTech and Moderna). Among patients without prior SARS-CoV-2 infection (n=148), the seropositivity rate was 86%. A majority (70%) of seropositive patients had maximum titers for anti-spike IgG antibodies at least 14 days after the second dose. No significant differences were observed between the two vaccines.

Lacson et al. (Apr 13, 2021). Immunogenicity of SARS-CoV-2 Vaccine in Dialysis. Pre-print downloaded Apr 22 from